52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Pfizer Says Phase 2/3 Trial Of COVID-19 Vaccine Has Enrolled 39,862 Participants
Biontech And Pfizer Initiate Rolling Submission To European Medicines Agency
Biontech Says Request For COVID-19 Vaccine Approval Could Be Filed End Of Oct.
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Biotechnology & Drugs
An der Goldgrube 12
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Pfizer Inc has said it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, opening up the possibility of a vaccine being available in the United States by the end of the year. Moderna and AstraZeneca are close behind the largest U.S...
One of the world's leading COVID-19 experimental vaccines produces a immune response in both old and young adults, raising hopes of a path out of the gloom and economic destruction wrought by the novel coronavirus.
A Brazilian pharmaceutical company said on Friday it has signed an agreement with the Russian Direct Investment Fund (RDIF) to produce Russia's Sputnik V vaccine against COVID-19 starting in the second half of November.
German biotech company CureVac said on Friday its potential vaccine against the coronavirus triggered an immune response in pre-clinical animal studies.
Germany is making preparations to start vaccinations against the coronavirus before the end of the year, Bild daily reported on Friday.
Pfizer Inc <PFE.N> and Johnson & Johnson <JNJ.N> are seeking input from a U.S. Food and Drug Administration advisory committee on retaining and attracting volunteers for COVID-19 vaccine trials after a vaccine becomes available, if they know they might receive a placebo.
Britain on Thursday said it would partner with an Oxford-based firm to provide testing for the T cell response of coronavirus vaccine candidates to try to assess their immune responses.
Ecuador has signed supply agreements with major pharmaceutical firms including Pfizer Inc and BioNTech to provide millions of COVID-19 vaccines, the health minister said on Wednesday, adding it is seeking talks with Chinese laboratories for more supplies.
Pfizer Inc <PFE.N> and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.
The S&P 500 posted a nominal gain on Friday as further clarity regarding the timeline for the development of a coronavirus vaccine and much better-than-expected retail sales data brought buyers back to the market.
Global shares bounced on Friday while safe havens such as the dollar were on the defensive as investors welcomed news that drugmaker Pfizer Inc <PFE.N> could have a coronavirus vaccine ready in the United States by the end of this year.
U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director...
Pfizer Inc <PFE.N> said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year.
The S&P 500 advanced on Friday as further clarity regarding the timeline for the development of a coronavirus vaccine and much better-than-expected retail sales data and brought buyers back to the market.
* Chilean peso up after central bank leaves rates unchanged * Argentina central bank lowers Leliq rate to 36% * Mexican peso outperforms Latam peers for the week (Updates prices throughout) By Shreyashi Sanyal Oct 16 (Reuters) - Latin American currencies rose on Friday after...
Global shares rose on Friday while safe-havens such as the dollar softened as investors welcomed news that drugmaker Pfizer Inc could have a coronavirus vaccine ready in the United States by the end of this year.
* Indexes up: Dow 0.87%, S&P 0.55%, Nasdaq 0.35% (Updates to late afternoon, changes dateline, byline)
* Indexes up: Dow 0.7%, S&P 0.4%, Nasdaq 0.1% (Updates to early afternoon)
The FTSE 100 snapped a four-day losing streak on Friday after an upbeat coronavirus vaccine update from Pfizer and signs Brexit talks might continue until the year end for a possible trade deal with the European Union.
European shares bounced on Friday on hopes that a vaccine for the novel coronavirus could be available in the United States before the end of the year, with a clutch of upbeat quarterly earnings also lifting sentiment after a torrid week.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.